Title |
Animal models of ulcerative colitis and their application in drug research
|
---|---|
Published in |
Drug Design, Development and Therapy, November 2013
|
DOI | 10.2147/dddt.s40107 |
Pubmed ID | |
Authors |
Daren Low, Deanna D Nguyen, Emiko Mizoguchi |
Abstract |
The specific pathogenesis underlying inflammatory bowel disease is complex, and it is even more difficult to decipher the pathophysiology to explain for the similarities and differences between two of its major subtypes, Crohn's disease and ulcerative colitis (UC). Animal models are indispensable to pry into mechanistic details that will facilitate better preclinical drug/therapy design to target specific components involved in the disease pathogenesis. This review focuses on common animal models that are particularly useful for the study of UC and its therapeutic strategy. Recent reports of the latest compounds, therapeutic strategies, and approaches tested on UC animal models are also discussed. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | <1% |
United Kingdom | 1 | <1% |
Canada | 1 | <1% |
Slovakia | 1 | <1% |
Japan | 1 | <1% |
Spain | 1 | <1% |
Unknown | 401 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 68 | 17% |
Student > Master | 61 | 15% |
Student > Bachelor | 48 | 12% |
Researcher | 41 | 10% |
Student > Postgraduate | 21 | 5% |
Other | 59 | 14% |
Unknown | 110 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 73 | 18% |
Biochemistry, Genetics and Molecular Biology | 51 | 13% |
Medicine and Dentistry | 44 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 40 | 10% |
Immunology and Microbiology | 33 | 8% |
Other | 44 | 11% |
Unknown | 123 | 30% |